GlassScriptPhysician profile
Brianna J Smith
NPI 1720432719
$2,896.82
in general payments reported to CMS, 2019-2025
31 companies · $905 in 2025
The $905 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $135 · 2022: $489 · 2023: $537 · 2024: $830 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,272.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $430.58 | 2021-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $374.12 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $334.40 | 2022-2025 | Trelegy Ellipta, Nucala |
| Grifols USA, LLC | $199.90 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Genentech USA, INC. | $154.54 | 2022-2025 | Xolair |
| Optinose US, INC. | $149.19 | 2021-2025 | |
| Pharming Healthcare, INC. | $137.84 | 2021-2025 | Ruconest |
| Genzyme Corporation | $129.23 | 2022-2025 | |
| Csl Behring | $128.32 | 2023-2024 | Haegarda, Hizentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.50 | 2021-2023 | Spiriva Respimat |
| Alk-Abello, INC | $84.25 | 2021-2023 | Timothy, Standardized, Standardized Mite D. Farinae, Alternaria Tenuis |
| Amgen INC. | $79.41 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $66.19 | 2023-2024 | Cuvitru, Takhzyro |
| Kaleo, INC. | $51.48 | 2022-2024 | Auvi-Q |
| Pfizer INC. | $48.85 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $47.81 | 2022 | |
| Novartis Pharmaceuticals Corporation | $39.02 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $38.29 | 2025 | Neffy |
| Abbott Laboratories | $29.55 | 2024 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $29.43 | 2022-2023 | Airduo Digihaler |
| Organon LLC | $28.77 | 2025 | Vtama |
| Biocryst US Sales Co., LLC | $27.91 | 2022 | |
| Incyte Corporation | $26.92 | 2025 | Opzelura |
| Octapharma USA, INC. | $24.33 | 2024 | Cutaquig |
| Dermavant Sciences, INC. | $23.22 | 2024 | Vtama |
| Paratek Pharmaceuticals, INC. | $21.49 | 2025 | Xhance |
| Aimmune Therapeutics, INC. | $21.37 | 2022 | |
| Lilly USA, LLC | $18.59 | 2025 | Ebglyss |
| Bio Products Laboratory USA, INC. | $18.53 | 2022 | |
| Hikma Pharmaceuticals USA | $16.62 | 2023 | Ryaltris |
| Phadia US INC. | $14.17 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brianna Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.